Genmab A/S
GNMSF
$310.63
-$0.88-0.28%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.16B | 896.00M | 1.06B | 925.00M | 925.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.16B | 896.00M | 1.06B | 925.00M | 925.00M |
| Cost of Revenue | 84.00M | 65.00M | 81.00M | 57.00M | 57.00M |
| Gross Profit | 1.07B | 831.00M | 977.00M | 868.00M | 868.00M |
| SG&A Expenses | 205.00M | 166.00M | 208.00M | 144.00M | 144.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 748.00M | 671.00M | 815.00M | 565.00M | 565.00M |
| Operating Income | 407.00M | 225.00M | 243.00M | 360.00M | 360.00M |
| Income Before Tax | 295.00M | 74.00M | 55.00M | 423.00M | 423.00M |
| Income Tax Expenses | -8.00M | 21.00M | 24.00M | 87.00M | 87.00M |
| Earnings from Continuing Operations | 303.00M | 53.00M | 31.00M | 336.00M | 336.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 303.00M | 53.00M | 31.00M | 336.00M | 336.00M |
| EBIT | 407.00M | 225.00M | 243.00M | 360.00M | 360.00M |
| EBITDA | 423.00M | 244.00M | 253.00M | 368.00M | 376.00M |
| EPS Basic | 4.94 | 0.84 | 0.50 | 5.44 | 5.44 |
| Normalized Basic EPS | 3.33 | 1.18 | 2.41 | 3.87 | 3.87 |
| EPS Diluted | 4.91 | 0.83 | 0.50 | 5.42 | 5.42 |
| Normalized Diluted EPS | 3.31 | 1.16 | 2.35 | 3.85 | 3.85 |
| Average Basic Shares Outstanding | 61.34M | 63.10M | 61.58M | 61.76M | 61.76M |
| Average Diluted Shares Outstanding | 61.71M | 63.86M | 63.12M | 61.99M | 61.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |